Literature DB >> 2941369

Differential modulation of the baroreceptor reflex by brain and plasma vasopressin.

T Unger, P Rohmeiss, G Demmert, D Ganten, R E Lang, F C Luft.   

Abstract

Plasma vasopressin sensitizes the baroreceptor reflex, whereas vasopressin given into the cerebral ventricle overrides the baroreceptor reflex by means of sympathetic stimulation. To test the hypothesis that arginine vasopressin stimulates two different receptor subtypes (V1 and V2) in the central nervous system, we measured the baroreceptor reflex (change in pulse interval vs change in blood pressure) after administering methoxamine (10-300 micrograms/kg i.v.) in conscious rats. Animals were pretreated either with a V1 vasopressin receptor antagonist administered intravenously or intracerebroventricularly, or with a V2 receptor antagonist administered intravenously. The central V1 antagonist caused sensitization of the baroreceptor reflex, whereas the intravenous V2 antagonist attenuated it. The intravenous V1 vasopressin antagonist had no effect on baroreceptor reflex sensitivity. When the experiments were repeated in rats with hereditary diabetes insipidus, neither antagonist influenced the baroreceptor reflex. Volume expansion lowered circulating vasopressin levels and also attenuated the baroreceptor reflex--effects similar to those observed with the intravenous V2 antagonist. We conclude that vasopressin sensitizes the baroreceptor reflex through V2 receptors accessible from the blood and inhibits the reflex through V1 receptors in the brain that cannot be reached from the blood. These observations suggest a direct interaction between hormonal and neuronal vasopressin in cardiovascular control.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941369     DOI: 10.1161/01.hyp.8.6_pt_2.ii157

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Evidence for involvement of central vasopressin V1b and V2 receptors in stress-induced baroreflex desensitization.

Authors:  Sanja Milutinović-Smiljanić; Olivera Šarenac; Maja Lozić-Djurić; David Murphy; Nina Japundžić-Žigon
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

2.  Vasopressin and 1-deamino-8-D-arginine-vasopressin (DDAVP) reduce elevated plasma catecholamine levels in rats with hypothalamic deafferentation.

Authors:  R Kvetnanský; B Lichardus; D Jezová; Z Oprsalová; G B Makara
Journal:  Cell Mol Neurobiol       Date:  1988-06       Impact factor: 5.046

Review 3.  The hypothalamic-neurohypophyseal system: from genome to physiology.

Authors:  D Murphy; A Konopacka; C Hindmarch; J F R Paton; J V Sweedler; M U Gillette; Y Ueta; V Grinevich; M Lozic; N Japundzic-Zigon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

4.  Vasopressin and oxytocin in control of the cardiovascular system.

Authors:  Nina Japundžić-Žigon
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

Review 5.  The NTS and integration of cardiovascular control during exercise in normotensive and hypertensive individuals.

Authors:  Lisete Compagno Michelini
Journal:  Curr Hypertens Rep       Date:  2007-06       Impact factor: 4.592

Review 6.  The Paraventricular Nucleus of the Hypothalamus in Control of Blood Pressure and Blood Pressure Variability.

Authors:  Bojana Savić; David Murphy; Nina Japundžić-Žigon
Journal:  Front Physiol       Date:  2022-03-16       Impact factor: 4.566

Review 7.  Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review.

Authors:  Nina Japundžić-Žigon; Maja Lozić; Olivera Šarenac; David Murphy
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.